E. Frigerio

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

P. Vasey, Stan B. Kaye, Rachel Morrison et al. · PubMed · 1999 · 691 citations

Pathology, Pharmacotherapy, Maximum Tolerated Dose +16

Polymer-bound camptothecin: initial biodistribution and antitumour activity studies

Valeria R. Caiolfa, Moreno Zamai, Antonio Fiorino et al. · Journal of Controlled Release · 2000 · 154 citations

Polymer-bound Camptothecin, Polymer-drug Conjugate, Medicine +3

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

Alison H. Thomson, P. Vasey, Lilian S. Murray et al. · British Journal of Cancer · 1999 · 81 citations · Full text

CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study

Gabriella Bottini, M Franceschi, Elio Scarpini et al. · Current Alzheimer Research · 2013 · 76 citations

Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid–liquid extraction

Simona Barattè, S. Sarati, E. Frigerio et al. · Journal of Chromatography A · 2003 · 60 citations

Pharmaceutical Science, Biochemistry, Semi-automated Liquid–liquid Extraction +14